ホワイトホーク・セラピューティクス
Whitehawk Therapeutics Inc
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.20 | $0 | -$15M |
| 2026 Q1 | -0.32 | $0 | -$22M |
| 2025 Q4 | -0.34 | $0 | -$17M |
| 2025 Q3 | -0.26 | $0 | -$15M |
| 2025 Q2 | -0.76 | $0 | -$53M |
| 2025 Q1 | 1.84 | $7M | -$12M |
| 2024 Q4 |
| -0.67 |
| $7M |
| -$15M |
| 2024 Q3 | -0.46 | $7M | -$16M |